UPCC 24420: ULTRA-V: Phase 2 Study to Assess | Clinical Research Studies Listing

UPCC 24420: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Recruiting

18 years - 99 years

All

Phase 2

1 participants needed

4 Locations

Brief description of study

This study tests the safety and effectiveness of the combination of ublituximab, umbralisib, and venetoclax. Patients with Chronic Lymphocytic Leukemia (CLL) will be invited to participate in this trial.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Chronic Lymphocytic Leukemia,cancer
Age: 18 years - 99 years
Gender: All

Updated on 30 Jan 2025. Study ID: 843678

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 24420: ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Brief description of study

Eligibility of study

Find a site

Interested in the study